leadf
logo-loader
viewTissue Regenix Group PLC

Tissue Regenix hails significant milestone as it ships new product line to first customer

The delivery of initial orders for OrthoPure XT comes less than six months after regulatory sign-off and in the face of some stiff headwinds

Tissue Regenix Group PLC -

Tissue Regenix Group PLC (LON:TRX) has said first delivery of its new OrthoPure XT product has taken place with further orders expected to be shipped early next year.

The regenerative medicines specialist noted that this represents a quick turnaround from approval (it received its CE Mark in June) to the sale of the first decellularized tendons.

Interest in Tissue’s technology was such that it landed its first UK order in August with a speciality supplier of orthopaedic and biologic products.

It has since targeted Europe, securing a partner in Poland, and is currently in discussions with other parties.

"Our plan is to establish an initial distribution network for OrthoPure XT and expand as procedural levels return,” said Tissue Regenix chief executive Daniel Lee in a statement.

“This will be a key product for the group in Europe and highlights the need, and demand, for biologic solutions outside of the current US market. It is a testament to the work of our processing and commercial teams that we have secured distribution agreements and delivery of the product has remained on-track despite the challenges presented during 2020," he added.

OrthoPure XT, which incorporates the company’s dCELL technology, is used in knee ligament reconstruction.

Quick facts: Tissue Regenix Group PLC

Price: 0.72 GBX

AIM:TRX
Market: AIM
Market Cap: £50.64 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Tissue Regenix Group PLC named herein, including the promotion by the Company of Tissue Regenix Group PLC in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

Tissue Regenix Group says 'maintaining level of sales is true testament to...

Tissue Regenix Group PLC's (LON:TRX) Daniel Lee talks to Proactive London about his experience in the sector, his new appointment as CEO as well the firm's performance for 2020.  In a trading update for the year to December 31, Lee says the revenues for the year will be £12.8mln, in line...

3 weeks, 2 days ago

2 min read